PDF factsheet
      Z

combined BRAF-MEK inhibitors in melanoma for all type of patients, clinical trials results

encorafenib plus binimetinib versus vemurafenib
COLUMBUS, 2018
NCT01909453
oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily
versus
oral vemurafenib 960 mg twice daily
patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutationopen label
Follow-up duration: 16.6 mo (median)
28 countries
trametinib and dabrafenib versus dabrafenib
Flaherty, 2012
NCT01072175
dabrafenib (150 mg) plus trametinib (1 or 2 mg)
versus
dabrafenib monotherapy
patients with metastatic melanoma and BRAF V600 mutations
COMBI-D (Long), 2014
NCT01584648
dabrafenib and trametinib
versus
dabrafenib monotherapy
previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation
trametinib and dabrafenib versus placebo
COMBI-AD, 2017
NCT01682083
dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months
versus
placebo
Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanomadouble-blind
trametinib and dabrafenib versus SOC
COMBI neo, 2018
NCT02231775

versus
trametinib and dabrafenib versus vemurafenib
COMBI-V (Robert), 2015
NCT01597908

versus
patients with metastatic melanoma with a BRAF V600 mutation
vemurafenib and cobimetinib versus vemurafenib
Larkin, 2014
NCT01689519
vemurafenib and cobimetinib
versus
vemurafenib and placebo
patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma

  Options


in first

in second

  Filter